Patents on Technologies of Human Tissue and Organ Regeneration from Pluripotent Human Embryonic Stem Cells

DSpace/Manakin Repository

Patents on Technologies of Human Tissue and Organ Regeneration from Pluripotent Human Embryonic Stem Cells

Citable link to this page

 

 
Title: Patents on Technologies of Human Tissue and Organ Regeneration from Pluripotent Human Embryonic Stem Cells
Author: Parsons, Xuejun H; Teng, Yang D; Moore, Dennis A; Snyder, Evan Y

Note: Order does not necessarily reflect citation order of authors.

Citation: Parsons, Xuejun H, Yang D Teng, Dennis A Moore, and Evan Y Snyder. 2011. “Patents on Technologies of Human Tissue and Organ Regeneration from Pluripotent Human Embryonic Stem Cells.” Recent Patents on Regenerative Medicine 1 (2): 142-163. doi:10.2174/2210297311101020142. http://dx.doi.org/10.2174/2210297311101020142.
Full Text & Related Files:
Abstract: Human embryonic stem cells (hESCs) are genetically stable with unlimited expansion ability and unrestricted plasticity, proffering a pluripotent reservoir for in vitro derivation of a large supply of disease-targeted human somatic cells that are restricted to the lineage in need of repair. There is a large healthcare need to develop hESC-based therapeutic solutions to provide optimal regeneration and reconstruction treatment options for the damaged or lost tissue or organ that have been lacking. In spite of controversy surrounding the ownership of hESCs, the number of patent applications related to hESCs is growing rapidly. This review gives an overview of different patent applications on technologies of derivation, maintenance, differentiation, and manipulation of hESCs for therapies. Many of the published patent applications have been based on previously established methods in the animal systems and multi-lineage inclination of pluripotent cells through spontaneous germ-layer differentiation. Innovative human stem cell technologies that are safe and effective for human tissue and organ regeneration in the clinical setting remain to be developed. Our overall view on the current patent situation of hESC technologies suggests a trend towards hESC patent filings on novel therapeutic strategies of direct control and modulation of hESC pluripotent fate, particularly in a 3-dimensional context, when deriving clinically-relevant lineages for regenerative therapies.
Published Version: doi:10.2174/2210297311101020142
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571164/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:22857021
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters